Sarcopenia and Androgens: A Link between Pathology and Treatment
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Sarcopenia, the age-related loss of skeletal muscle mass and function, is becoming more prevalent as the lifespan continues to increase in most populations. As sarcopenia is highly disabling, being associated with increased risk of dependence, falls, fractures, weakness, disability, and death, development of approaches to its prevention and treatment are required. Androgens are the main physiologic anabolic steroid hormones and normal testosterone levels are necessary for a range of developmental and biological processes, including maintenance of muscle mass. Testosterone concentrations decline as age increase, suggesting that low plasma testosterone levels can cause or accelerate muscle- and age-related diseases, as sarcopenia. Currently, there is increasing interest on the anabolic properties of testosterone for therapeutic use in muscle diseases including sarcopenia. However, the pathophysiological mechanisms underlying this muscle syndrome and its relationship with plasma level of androgens are not completely understood. This review discusses the recent findings regarding sarcopenia, the intrinsic, and extrinsic mechanisms involved in the onset and progression of this disease and the treatment approaches that have been developed based on testosterone deficiency and their implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 3×
“PREVALENCE OF SARCOPENIA The term sarcopenia was first proposed in 1989 by Irwin Rosenberg to describe a multifactorial syndrome that occurs with age and results in loss of skeletal muscle mass and function (3, 4).”
BackgroundMethodInfluentialSkeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 2×
“CELLULAR AND MOLECULAR MECHANISMS UNDERLYING SARCOPENIA Although the pathophysiology of sarcopenia remains under investigation, two main groups of factors have been identified as responsible for its development: (1) intrinsic factors at the cellular level, such as mitochondrial malfunction and oxidative stress; (2) sy…”
BackgroundFeldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“Androgen levels as extrinsic factor for sarcopenia In addition to a natural decrease in testosterone levels due to age, abnormal levels of plasma testosterone are observed in men suffering from late-onset hypogonadism, loss of testicular mass, and endocrine diseases involving low androgen production, accelerated testo…”
BackgroundVisser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Skeletal Muscle Cutpoints Associated with Elevated Physical Disability Risk in Older Men and Women
Janssen, I. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh058 · Cited by 1,190
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“While elevated plasma androgen concentrations are known to induce skeletal muscle hypertrophy (35), the cellular mechanisms by which testosterone increases skeletal muscle mass remain under investigation.”
BackgroundSelf-renewal and expansion of single transplanted muscle stem cells
Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., & Blau, H. M. (2008) · Nature · doi:10.1038/nature07384 · Cited by 901 · cited 2×
“Moreover, these stem cells generate a massive proliferation during muscle injury (100).”
Background
Cited by
Wilkinson, D. J., Piasecki, M., & Atherton, P. J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.005 · Cited by 874
Association between low testosterone levels and sarcopenia in cirrhosis: A cross-sectional study
Moctezuma-Velázquez, C., Low, G., Mourtzakis, M., Ma, M., Burak, K. W., Tandon, P., & Montano-Loza, A. J. (2018) · Annals of Hepatology · doi:10.5604/01.3001.0012.0930 · Cited by 70
From mitochondria to sarcopenia: role of 17β-estradiol and testosterone
Tian, X., Lou, S., & Shi, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156583 · Cited by 54
Pathophysiological analyses of skeletal muscle in obese type 2 diabetes SDT fatty rats
Kemmochi, Y., Ohta, T., Motohashi, Y., Kaneshige, A., Katsumi, S., Kakimoto, K., Yasui, Y., Anagawa-Nakamura, A., Toyoda, K., Taniai-Riya, E., et al. (2018) · Journal of Toxicologic Pathology · doi:10.1293/tox.2017-0064 · Cited by 23
Metadata
- Authors
- Basualto-Alarcón, C., Varela, D., Duran, J., Maass, R., & Estrada, M.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2014-12-18
- Volume
- 5
- Pages
- 217-217
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2074657049
- Cited by
- 79
- References
- 30
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenia and Androgens: A Link between Pathology and Treatment. https://app.cochat.ai/papers/10.3389/fendo.2014.00217
- The paper
- Basualto-Alarcón, C., Varela, D., Duran, J., Maass, R., & Estrada, M. (2014). Sarcopenia and Androgens: A Link between Pathology and Treatment. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2014.00217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.